Pain Management

Dr. Jahr has been at the forefront the conduct of definitive preclinical and clinical studies involving the application of hemoglobin based oxygen carriers in the treatment of hemorrhage and orthopedic surgery. He is the world’s foremost expert in the use of advanced diagnostic techniques in the study of the impact of volumizing fluids and HBOCs on coagulapathy, and related thrombin and platelet function. He has served as principal investigator in Phase I trials of Alliance Corporations’ Perflubon™, Phase II trials of Hemosol’s Hemolink™, and Phase II and Phase III trials of Biopure’s HemoPure™ product. Dr. Jahr has previously studied OxyVita®’s impact on coagulapathy in ex vivo studies and reported his findings in the Journal of Cardiothoracic and Vascular Anesthesia, Vol 22:1, 34-39 (February, 2008). Throughout his extraordinary professional career, Dr. Jahr has been interested in the use of resuscitative fluids, blood transfusions, and intervention in the treatment of severe trauma, and the clinical efficacy of the use of blood substitutes, including perfluorocarbon technologies and hemoglobin based oxygen carriers to reduce the need for blood transfusions in clinical practice. He has been the principal investigator in over 30 clinical trials, has published over 150 studies, abstracts, review articles and case studies. He has served on the editorial review boards of Anesthesiology Review, American Journal of Anesthesiology, American Journal of Therapeutics, Journal of Cardiovascular Pharmacology and Therapeutics, Journal of Clinical Anesthesiology, Critical Care Medicine, American Journal of Physiology: Hear and Circulatory Physiology, Hematological, Anesthesiology, British Journal of Anesthesiology, and Vascular Pharmacology, and regularly lectures on issues regarding anesthesiology, oxygen therapeutics, and the management of blood products in surgical operations. Dr. Jahr received his undergraduate degree in Biology from Hamilton College, Clinton, NY Cum Laude, and with Honors, and his medical degree from New York Medical College, Valhalla, NY.

As a practicing Anesthesiologist, providing care personally, and supervising Anesthesiology Residents and Nurse Anesthetists, I have first-hand knowledge and experience in dealing with devastating traumatic hemorrhagic shock (THMS). With poor survival due to inadequate current resuscitation fluid used in the field, a more effective solution is required for improving outcome. As Interim Chair of Anesthesiology for the past 23 years and Trauma Clinical Trials Research Director at a traditionally underserved minority institution for two years, I witnessed how disparities in healthcare lead to worse outcomes in trauma. For the past 23 years, in basic science, translational and clinical models/trials, I have devoted my energy to understanding the pathophysiology, pharmacology and management of THS with over 100 peer reviewed publications, especially with regard attention to oxygen carriers, and specifically to the coagulopathic effects of these products. Notably, recently I led a Phase III clinical trial of a leading HBOC product which resulted in a publication, which is considered as one of the key publications in the field (Jahr et al., 2008). This work while presenting an Invited Plenary Lecture at the XII International Symposium on Blood Substitutes, Parma, Italy, entitled: “Clinical and Translational Advances in Blood Substitutes--One Investigator’s Perspective”, I proposed a Consortium approach for new development of blood substitute science. My expertise, extensive experience, and leadership roles in the resuscitation fluid research has enabled me to guide this form a Consortium of world class thought leaders and researchers in this area, and based on the goals of the consortium, to transition from oxygen carriers, to study the therapeutic potential provide outstanding science in a transformational area of multifunctional resuscitation fluids, (specifically a Small volume Multifunctional Emergency Resuscitation Fluid (: SMERF) consisting of a plasma expander, an oxygen carrier, coagulation factors and other beneficial mediators as a potential universal resuscitation fluid for field treatment of THS. Potential bias due to conflict-of-interest issues for industry sponsored investigators has been well recognized. Therefore, to conduct objective evaluations, SMERF must be studied without the influence of component manufacturers of the components (oxygen carrier, coagulation factors, fluids, other beneficial mediators) and be able to be reported in an unbiased way; the independence of consortium investigators will allow objective assessment of candidate SMERFs. Further, the safety and efficacy of candidate SMERFs will be evaluated by blinding of test materials and adoption of randomized study designs, similar to clinical trials (but uncommon in basic/translational research) The development of a model that includes blinded testing of the candidate SMERF products, amongst the 4 sites with well-established stellar scientific models and publications in this exact area, to vet these products and evaluate safety and efficacy in translational models is unparalleled. This project and call provide an outstanding platform on which to create, develop, and study this novel SMERF, so that a final product will emerge that can be vetted and approved by the Food and Drug Administration (FDA) for an IND Investigational New Drug (IND) Application, leading into FDA sponsored guided human Phase I through III trials, and eventual approval for human use. Consultant scientists from the FDA and the UCLA Director of Clinical and Translational Science Institute (CTSI) will participate in all critical decision points during the conduct of the grant. The potential for this fluid is truly revolutionary and if successful, will transform the field of resuscitation medicinal and allow for survival of trauma victims. The potential for this fluid is truly revolutionary and if successful, will transform the field of resuscitation medicine and allow for improved survival of trauma victims. My recent training in Executive Leadership at the UCLA Anderson School of Management will enable me to leverage the knowledge and abilities gained, to conduct the science and administration of this transformational grant in an exemplary manner. In summary, I have the expertise, experience and leadership to lead and manage the proposed research project to a successful solution.

Dr. Yaksh joined UCSD in 1988 as Professor and Vice Chairman for Research in the Department of Anesthesiology and Professor of Pharmacology. He became a Distinguished Professor in the School of Medicine in 2004. His laboratory at the Medical center in Hillcrest continues its active research in pain and in the development of analgesic drugs.

Pain, Analgesics, Opioid Pharmacology

Robert J. Gatchel, PhD, ABPP, is professor in the Department of Psychology, College of Science, at the University of Texas at Arlington. He is the Director of the Center for Excellence for the Study of Health & Chronic Illness at the University of Texas at Arlington, as well as Director of Biopsychosocial Research, Osteopathic Research Center, University of North Texas Health Science Center. He also is clinical research program consultant at the Eugene McDermott Center for Pain Management at the University of Texas Southwestern Medical Center at Dallas. Dr. Gatchel is a member of the Practical Pain Management Editorial Board.

Comorbidity of Physical and Mental Health Conditions. Etiology, Assessment, and Treatment of Chronic Pain Behavior. Evaluation of Stress-Management Treatment Techniques. Psycho physiological Concomitants of Stress and Emotion.

Prof. Dr. Alireza Heidari, Ph.D., D.Sc. is a Full Professor and Academic Tenure of Chemistry at California South University (CSU), Irvine, California, USA. He has got his Ph.D. and D.Sc. degrees from California South University (CSU), Irvine, California, USA. Furthermore, he has double postdocs in Project Management, Oncology, Human Cancer Tissues and Synchrotron Radiation from Monash University, Melbourne, Victoria, Australia and also in Nanochemistry and Modern Molecular Electronic–Structure Computations Theory from California South University (CSU), Irvine, California, USA.He has participated at more than one hundred fifty reputed international conferences, seminars, congresses, symposiums and forums around the world as yet. Also, he possesses many published articles in Science Citation Index (SCI)/International Scientific Indexing (ISI) Journals. It should be noted that he has visited many universities or scientific and academic research institutes in different countries such as United States, United Kingdom, Canada, Australia, Scotland, Ireland, Netherlands, Belgium, Denmark, Greece, Russia, Estonia, Turkey, France, Swiss, Germany, Sweden, Italy, Austria, Hungary, Poland, Spain, Portugal, Mexico, Japan, Malaysia, Thailand, Taiwan, South Korea, China, India, Qatar, United Arab Emirates, etc. as research fellow, sabbatical and volunteer researcher or visitor and so on heretofore. He has a history of several years of teaching for college students and various disciplines and trends in different universities. Moreover, he has been a senior advisor in various industry and factories. He is expert in many computer programs and programming languages. Hitherto, he has authored more than twenty books and book chapters in different fields of Chemistry. Syne, he has been awarded more than seven hundreds reputed international awards, prizes, scholarships and honors. Heretofore, he has multiple editorial duties in many reputed international journals, books and publishers. Hitherward, he is a member of more than two hundreds reputed international academic–scientific–research institutes around the world. In addition, he is member of the Nobel committee for Chemistry. It should be noted that he is currently the President of American International Standards Institute (AISI), Irvine, California, USA and also Director of the BioSpectroscopy Core Research Laboratory at California South University (CSU), Irvine, California, USA.

Biophysical Chemistry, Biomolecular Spectroscopy, Quantum Chemistry, Nanochemistry, Modern Electronic Structure Computations, Theoretical Chemistry, Mathematical Chemistry, Computational Chemistry, Vibrational Spectroscopy, Molecular Modelling, Ab initio & Density Functional Methods, Molecular Structure, Biochemistry, Molecular Simulation, Pharmaceutical Chemistry, Medicinal Chemistry, Oncology, Synchrotron Radiation, LASER, Anti–Cancer Nano Drugs, Nano Drugs Delivery, ATR–FTIR Spectroscopy, Raman Spectroscopy, Intelligent Molecules, Molecular Dynamics, Biosensors, Biomarkers, Molecular Diagnostics, Numerical Chemistry, Nucleic Acids, DNA/RNA Monitoring, DNA/RNA Hypermethylation, Human Cancer Tissues, Human Cancer Cells, Tumors, Cancer Tissues, Cancer Cells, etc

Dr. Jabbari is a Professor Emeritus of Neurology. Dr. Jabbari's clinical interests include: Parkinson's disease; pharmacologic treatment and DBS treatment, clinical research Movement disorders; restless legs syndrome, spinocerebellar ataxias/degenerations, gait disorders, dystonias, tremors, Huntington's disease, Tourette syndrome and tardive dyskinesias, treatment of refractory medical and neurological disorders with botulinum toxins; chronic migraine , tardive dyskinesias, spasticity related to stroke, multiple sclerosis, cerebral palsy, focal pain syndromes ( postherpetic or posttraumatic neuralgia, planar faciitis, low back pain, myofacila pain syndrome)

Botulinum Toxins; Dystonia; Electrophysiology; Movement Disorders; Muscle Spasticity; Neurology; Parkinson Disease; Tremor; Dyskinesias; Deep Brain Stimulation

Dr. Feng Tao is an Associate Professor in the Department of Biomedical Sciences at Texas A&M University College of Dentistry. Dr. Tao received his RO1 award and Independent Scientist Award from NIH in 2012 and 2014, respectively. He has published more than 40 papers in peer-reviewed professional journals and he is serving as an editorial board member for some professional journals.

Biomedical Sciences, Research and Development in Spinal cord injury and Neuropathic Pain

Bimal Roy Krishna is currently a Professor and Director of Pharmacology at the College of Osteopathic Medicine, Touro University Nevada, USA. He has obtained his Bachelors of Science in Pharmacology and Physiology and Doctor of Philosophy from Monash University in Australia. He also teaches for the Step 1-USMLE and COMLEX reviews for Kaplan Medical throughout the United States and in UAE, Europe, Saudi Arabia, India, Mexico and Caribbean. He has been teaching online for Kaplan University for over 7 years and has contributed to numerous publications and is a Member of a number of organizations including Fellow-American College of Clinical Pharmacology. His research concern is on maternal and neonatal pharmacology specifically looking at materno-fetal transfer utilizing the perfused human placental and cultured syncytiotrophoblast model.

Human Placental Function Immunological Responses in Placental Tissue Natural and Complementary Medicine

Dr. Zhonghui Guan is an anesthesiologist and pain management specialist at the Pain Management Center at UCSF Medical Center. He specializes in treating chronic pain, including low back pain and neck pain, neuropathic pain, complex regional pain syndrome, failed back surgery syndrome and cancer pain.

In his research, he focuses on better understanding gene expression regulation in chronic pain. He earned a medical degree at Peking Union Medical School in Beijing, China, and completed an anesthesia residency at Massachusetts General Hospital in Boston, followed by a pain management fellowship at UCSF. He is a member of numerous professional organizations, including the American Society of Anesthesiologists, California Society of Anesthesiologists and Society for Neuroscience. He is an assistant professor in residence at UCSF.

Rene Przkora, MD, PhD, MMS, joined the University of Florida faculty as an associate professor in anesthesiology and pain medicine in 2014. He is the fellowship director of the multidisciplinary pain medicine fellowship program of the University of Florida. Before arriving at UF, he spent time at the University of Texas Medical Branch as assistant professor in anesthesiology and pain medicine as well as the assistant director of the pain medicine fellowship and the education director of the Patient Simulation Center. He finished a 2-year post-doctoral research fellowship at the University of Texas Medical Branch. He arrived at the University of Florida in 2006 and completed his residency in anesthesiology in 2010. Dr. Przkora was a fellow in pain medicine at the Massachusetts General Hospital, Harvard University, Boston and graduated in 2011. He finished his post-doctoral training by receiving a certificate in business administration from the American Society of Anesthesiology. Dr. Przkora is board certified in pain medicine and anesthesiology. He is a member of the American Society of Anesthesiologists, the American Academy of Pain Medicine, the American Society of Regional Anesthesia and Pain Medicine, and the International Anesthesia Research Society. Dr. Przkora is a junior editor for the American Board of Anesthesiology and a reviewer for scientific journals.

Pain Medicine, Anesthesiology Education, Functional Outcomes, Novel Methods and Their Combination to Assess Pain Treatment in Older Adults, Evaluation of Pain Treatment in Older Adults, Preserving Muscle Mass and Function in Older Adults, Education in Practice Management – Pain Medicine, Simulation and Education.

.

.

Dr. Nagy his graduation as an MD at University Medical School Debrecen, Hungary in 1982, Dr Nagy started to work as a neuroscientist. He obtained his PhD at the Hungarian Academy of Sciences in 1996. Recently he has also obtained the title of Dr. Habil. Dr Nagy has been working at Imperial College London since 1998, where he is one of the leading basic pain scientists. His pioneering work on heat transduction mechanisms and interactions between the endovanilloid and endocannabinoid systems has significantly contributed to the knowledge, which underlies the recent development of novel pharmacological approaches for pain control.

Transduction mechanisms: Dr Nagy has been working on transduction mechanisms in primary sensory neurons for more than 10 years. Currently Dr Nagy and his co-workers are interested in the mechanisms in mechanotransduction, particulalry in those which are involved the development of inflmmatory visceral hyper-reflexia. Endocannabinoid and endocannabinoid system: In order to utalise the potential of the endovanilloid and endocannabinoid systems for pain control, Dr Nagy and his co-workers study the role of various enocannabinoid/endovanoilloid molecules on the rugulation of nociceptive processing in primary sensory neurosn and the spinal cord. In this work they pay particular attention on the role of anandamide, by studying the actions and metabolism of this molecule. Nociceptive mechanisms in burn injury: In order to increase our understanding of the peripheral signalling mechanisms involved in the development of burn injury-associated pain, and to identify new target(s) for the development of novel analgesics for controlling burn injury-associated pain, Dr Nagy' laboratory is engaged in studies on signalling between agents accumulating in burnt tissues and sensory nerve endings innervating burnt tissues. In this work, Dr Nagy and his co-workers generate metabolomic and gene expression tissue databases of various degrees of burn injury (volunteer, burn-injured patients and rats) and rat primary sensory neurons, respectively. Analysing these databases will reveal putative targets for new therapeutic approaches to control pain in burn-injured patients. Headache: Dr Nagy has recently started to study mechanisms involved in the development of tension headache and migraine. He and his co-workers are particulalry interested in the role of hypothalamus, and mechanotransduction in trigeminal ganglionic neurons in the development of headache.

Dr. Brinkers has completed his MD at the university of Bonn. His postdoctoral studies are based on the habilitation thesis about the influence of CL on pain therapy. He is now senior house officer at the pain clinic of the university Magdeburg.

.

Dr. Robert Gyula Almasi began his postgraduate studies at “Kaposi Mor” Teaching Hospital in Hungary and specialized in Anesthesiology and Intensive Care. He held various lectures in the Faculty of Health Sciences at Pecs University. He was interested in acute and chronic pain management and joined the Institute of Pharmacology at University of Pecs Medical School as Associate Researcher in the Program of Neuroscience, Pain Pharmacology. In 2008 he received a Ph.D.from the same university. He was the Head of Dept. of Anesth. and Pain Management. Dr. Almasi was studying interventional pain management and ultrasound-guided peripheral nerve blockade techniques. He joined the Institute of Anaesthesiology and Intensive Care at Pecs University as a practicing regional anesthesiologist and pain expert and became a Senior Lecturer teaching various lectures and courses mainly in pain pharmacology, pain management, and regional anesthesia. He has been a member of IASP since 2006.With his colleagues and Ph.D. students his recent research interests include studying the effects of peripheral nerve blockades on perioperative and chronic pain, and the endocannabinoids

.

Prof. Sinerik Ayrapetyan has completed his PhD in Cell Biophysics in the Institute of Physiology of Ukraine Academy of Sciences, Kiev. He is the head of Research Council and the coordinator of UNESCO Chair in Life Sciences at Life Sciences International Postgraduate Educational Center, Yerevan, Armenia. His current research interest is “Intracellular Signaling System in Norm and Pathology”. He has published 7 international books and 115 papers. He is an Editor in Chief of the journal “Bioavailability and Bioequivalence”, and a member of editorial board of the journals: "Electromagnetic Biology and Medicine", "Journal of International Dental and Medical Research", “ISRN Biophysics”, “Advances in Life Sciences", “Applied Pharmacy”, “European Journal of Biophysics”, “Biochimica et Biophysica Acta” etc. He is a member of International Coordination Council of WHO and number of professional international societies. Abstract

.

.

.

Prof. Dr Syed Azhar Syed Sulaiman obtained his undergraduate degree from Universiti Sains Malaysia and later pursue Doctor of Pharmacy Degree from Michigan USA.He worked as junior lecturer for 2 years then he was elected to the deputyDean and later Dean School of Pharmaceutical Sciences Universiti Sains Malaysia from 2002 until 2012. He is actively involved in teaching clinical pharmacy in Malaysia and various countries in Asia Pacific. He was invited by the faculty and schools of pharmacy namely in Iran, India, Turki, Vietnam, China, Jordan, Hong Kong, Taiwan, South Africa, Indonesia, Thailand, Philippines, Mongolia, India, Pakistan, Emirates,Sudan and few other countries to teach undergraduates and Master in Clinical Pharmacy program. In the countries he is also actively being invited to numerous of public and private universities to teach clinical pharmacy.

He is also actively involved in research activities involving Palm oil tocotrienol for diabetes, Alzheimer, peripheral neuropahty ; halal concept of pharmaceutical products, production of new insulin like structure for diabetes product from frog and few other research areas. He has produced more that 2 dozens PhD’s and master in clinical pharmacy by research and published more then 200 papers in various journals and abstracts around the world. He is also the editor and committee members for various journals in Malaysia, Indonesia, Mongolia, Canada, India and few others around the globe.

.

.

Mohamed Eddouks is Professor at Moulay Ismail University, Faculty of Sciences and Techniques Errachidia, Morocco. He is a researcher in Physiology and Pharmacology with a Master Degree in Metabolic and Molecular Endocrinology from University of Paris vi, a specialized certificate in Endocrine Pharmacology from University of Paris vii and PhD degrees in Physiology and Pharmacology from University of Liege, Belgium and Sidi Mohammed Ben Abdellah University, Fez, Morocco. After his post-doctoral fellowship at Department of Physiology, Faculty of Medicine of Montreal, Canada, he is working for the last 16 years on medicinal plants. His work on antidiabetic and antihypertensive plants is well recognized globally. His research focuses on ethnobiological as well as pharmacological issues in the use of Moroccan medicinal plants for the treatment of diabetes mellitus, obesity and hypertension. His contribution to this field includes four international books and more than 80 peer-reviewed articles and book chapters of international repute. He has been honored with the first Prize of Scientific Research in 2008 by the Moroccan Association of Research and Development and the first Prize of the Federation of Arab Scientific Councils in 2016. He has been the Dean of Polydisciplinary Faculty of Errachidia from 2008 to 2012.

He is Guest Editor of American Journal of Pharmacology and Toxicology, Lead Guest Editor of an annual special issue published by Evidence-Based and Complementary Alternative Medicine, Regional Editor of the Following journals: American Journal of Food Technology, Journal of Applied Sciences, Trends in Applied Sciences Research and Singapore Journal of Scientific research, Member of Editorial Board of several international journals.

Dr. Farnad Imani is an associate professor with sixteen years' experience in academic postgraduate teaching in anesthesiology and pain medicine. He is chairman of department of anesthesiology and pain medicine in Tehran University of Medical Sciences (TUMS). He is founder of academic pain fellowship in Iran at 2006, and established the pain ward and interventional pain operation room in Rasoul Akram Medical Center at the first time in Iran. Dr. Imani has passed a course of interventional pain procedures in Texas Tech University, USA, in 2008, and is a Fellowship of the Interventional Pain Practice (FIPP) and secretory of World Institute of Pain (WIP), Iran section. He is founder and president of the Iranian Society of Regional Anesthesia and Pain Medicine (ISRAPM) from 2007 until now. Also, he conducts numerous seminars in the field of Interventional Pain Management, and was chairman of some Congresses of Interventional Pain Medicine. Dr Imani is pioneer of some Interventional Pain Procedures, such as percutaneous disc decompression, kyphoplasty, epiduroscopy, and radiofrequency (RF) neurolysis in Iran. He has conducted several workshops on interventional pain procedures, and invited speaker for several International congresses. Dr Imani is founder, chairman and editor in chief of Anesthesiology and Pain Medicine, which is the official Journal of ISRAPM. The journal welcomes all kinds of manuscripts which relevant to anesthesiology and pain Medicine field. He is the author of several papers in national and international journals, and books in the fields of anesthesiology and pain medicine (Persian language). He is going to authorize a pain book as the first comprehensive pain textbook in Persian language. Dr. Imani is the medical director and founder of the Mahya Pain Clinic. Until today, he continues to strive to be at the forefront for the treatment all spine and pain disorders. His passion for providing the most advanced medical and interventional pain technologies has made him well recognized in the field of pain management.

Interventional Pain Management Percutaneous spinal pain procedures Cancer pain management Chronic pain management Acute postoperative Pain Management.